Perceptive solutions to anti-filarial chemotherapy of lymphatic filariasis from the plethora of nanomedical sciences

References

• Wagner V, Dullaart AK, Zweck A, et al. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211–7
   PubMed Web of Science ®Google Scholar
• Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 2009;4:105–18
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Tőke ER. Nanomedicine applications towards the cure of HIV. Nanomedicine 2013;9:28–38
   PubMed Web of Science ®Google Scholar
• Pourmand A, Pourmand MR, Wang J, et al. Application of nanomedicine in emergency medicine; point-of-care testing and drug delivery in twenty-first century. DARU J. Pharm Sci 2012;20:20–6
   Web of Science ®Google Scholar
• Owais M, Misra-bhattacharya S, Haq W, et al. Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. J Drug Target 2003;11:247–51
   PubMed Web of Science ®Google Scholar
• Bajpai P, Vedi S, Owais M, et al. Use of liposomized tetracycline inelimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J Drug Target 2005;13:375–81
   PubMed Web of Science ®Google Scholar
• Dangi A, Dwivedi V, Vedi S, et al. Improvement in the antifilarial efficacy of doxycycline and rifampicin by combination therapy and drug delivery approach. J Drug Target 2010;18:343–50
   PubMed Web of Science ®Google Scholar
• Kirthi AV, Rahuman AA, Rajakuma G, et al. Acaricidal, pediculocidal and larvicidal activity of synthesized ZnO nanoparticles using wetchemical route against blood feeding parasites. Parasitol Res 2011;5:47–56
   Google Scholar
• Ramyadevi J, Jeyasubramanian K, Marikani A, et al. Copper nanoparticles synthesized by polyol process used to control hematophagous parasites. Parasitol Res 2011;5:56–67
   Google Scholar
• Salunkhe RB, Patil SV, Patil CD, et al. Larvacidal potential of silver nanoparticles synthesized using fungus Cochliobolus lunatus against Aedes aegypti and Anopheles stephensi Liston. Parasitol Res 2011;109:823–31
   PubMed Web of Science ®Google Scholar
• Ali M, Afzal M, Verma M, et al. Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi. Parasitol Res 2013;2:2933--43. doi: 10.1007/s00436-013-3466-4
   Google Scholar
• Edwards G, Krishna S. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur J Clin Microbiol Infect Dis 2004;23:233–42
   PubMed Web of Science ®Google Scholar
• Singh PK, Ajay A, Kushwaha S, et al. Towards novel antifilarial drugs: challenges and recent developments. Future Med Chem 2010;2:251–83
   PubMed Web of Science ®Google Scholar
• Melrose WD. Chemotherapy for lymphatic filariasis progress but not perfection. Expert Rev Anti Infect Ther 2003;1:571–7
   PubMedGoogle Scholar
• Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiol Rec 2012;87:346–56
   Google Scholar
• Anitha K, Shenoy RK. Treatment of lymphatic filariasis: current trends. Continuing Med Education 2001;67:60–5
   Google Scholar
• Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine – an overview. Fundam Clin Pharmacol 2009;23:263–9
   PubMed Web of Science ®Google Scholar
• Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des 2010;16:1882–92
   PubMed Web of Science ®Google Scholar
• Darshan S, Tyshenko MG. Identifying recent trends in nanomedicine development. Int J Nanotechnol 2010;7:173–86
   Web of Science ®Google Scholar
• Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov Today 2005;23–24:1667–73
   Web of Science ®Google Scholar
• Takakura Y. Development of drug delivery systems for macromolecular drugs. Yakugaku Zasshi 1996;116:519–32 (in Japanese)
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008;36:43–8
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235–49
   PubMed Web of Science ®Google Scholar
• García-Rodriguez JJ, Torrado J, Bolás F. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes. Parasite 2001;8:88–90
   Google Scholar
• Gaur RL, Dixit S, Sahoo MK, et al. Anti-filarial activity of novel formulations of albendazole against experimental brugian filariasis. Parasitology 2007;134:537–44
   PubMed Web of Science ®Google Scholar
• Casulli A, Morales MAG, Gallinella B, et al. 2-Hydroxypropyl-β-cyclodextrin improves the effectiveness of albendazole against encapsulated larvae of Trichinella spiralis in a murine model. J Antimicrob Chemother 2006;58:886–90 Available from: http://jac.oxfordjournals.org/content/58/4/886.full - aff-2
   PubMed Web of Science ®Google Scholar
• Bhatt AD, Pethe AM. Nanotechnology: a promising drug delivery for poorly water soluble drugs. J Pharm Res 2010;3:817–48
   Google Scholar
• Liu Y, Xie P, Zhang D, Zhang Q. A mini review of nanosuspensions development. J Drug Target 2012;20:209--23
   Google Scholar
• Gupta AK, Sehrawat SK. Bioavailability enhancement of poorly water soluble drugs: A review. Int J Pharm Life Sci 2011;2:640--50
   Google Scholar
• Rahman MA, Harwansh R, Mirza MA, et al. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv 2011;8:330–45
   PubMed Web of Science ®Google Scholar
• Park YD, Ōya A, Ōtani S. Factors governing the solubility of mesophase into pitch distillate. Fuel 1983;62:1499–502
   Web of Science ®Google Scholar
• Bassissi F, Lespine A, Alvinerie M. Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration. Parasitol Res 2006;98:244–9
   PubMed Web of Science ®Google Scholar
• Wen H, New RR, Muhmut M, et al. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 1996;113:111–21
   PubMed Web of Science ®Google Scholar
• Guerra-caceres JG, Bryceson ADM, Quakyi I, et al. Studies on the mechanisms of adverse reactions produced by diethylcarbamazine in patients with onchocerciasis – Mazzotti reaction. Parasite Immunol 1980;2:121–31
   Web of Science ®Google Scholar
• Bindu M Boddupalli, Mohammed ZNK, Ravinder A Nath, et al. Mucoadhesive drug delivery system: an overview. J Adv Pharm Technol Res 2010;1:381–7
   PubMedGoogle Scholar
• Hombach J, Bernkop-Schnürch A. Mucoadhesive drug delivery systems. Exp Pharmacol 2010;197:251–66
   Google Scholar
• Arora S, Ali J, Ahuja A, et al. Floating drug delivery systems: a review. AAPS PharmSciTech 2005;6:372–90
   PubMed Web of Science ®Google Scholar
• Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000;3:235–59
   Web of Science ®Google Scholar
• Suresh K Maurya, Pathak K, Vikas Bali. Therapeutic potential of mucoadhesive drug delivery systems – an updated patent review. Recent Pat Drug Deliv Formul 2010;4:256–65
   PubMedGoogle Scholar
• Singla AK, Chawla M, Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev Ind Pharm 2000;9:913–24
   Web of Science ®Google Scholar
• Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 2002;15:355–66
   Web of Science ®Google Scholar
• Gadkowski BL, Stout JE. Pharmacokinetics of rifampicin. Clin Infect Dis 2007;44:618–9
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198–205
   PubMed Web of Science ®Google Scholar
• Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008;77:311–9
   PubMed Web of Science ®Google Scholar
• Mehra NK, Mishra V, Jain NK. Receptor-based targeting of therapeutics. Ther Deliv 2013;4:369–94
   PubMedGoogle Scholar
• Luo G, Yu X, Jin C, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010;385:150–6
   PubMed Web of Science ®Google Scholar
• Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001;6:667–80
   Web of Science ®Google Scholar
• Hauff P, Reinhardt M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231:667–73
   PubMed Web of Science ®Google Scholar
• Cuong NV, Hsieh MF. Molecular targeting of liposomal nano-particles to lymphatic system. Curr Cancer Drug Targets 2011;11:147–55
   PubMed Web of Science ®Google Scholar
• Shivakumar HN, Desai BG, Deshmukh G. Design and optimization of diclofenac sodium controlled release solid dispersions by response surface methodology. Indian J Pharm Sci 2008;70:22–30
   PubMed Web of Science ®Google Scholar
• Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release 2008;132:153–63
   PubMed Web of Science ®Google Scholar
• Gupta RC, Bansal SS, et al. Controlled-release systemic delivery – a new concept in cancer chemoprevention. Carcinogenesis 2012;8:1608
   Web of Science ®Google Scholar
• Shenoy RK. Varghese J, Kuttikkal VV, et al. The efficacy, tolerability and diethylcarbamazine fortified salt in treatment of the microfilaraemias of brugian filariasis: an open, hospital based safety of the study. Ann Trop Med Parasitol 2003;92:285--93
   Google Scholar
• Pani SP, Reddy GS, Das LK, et al. Tolerability and efficacy of single dose of albendazole or diethylcarbamazine (DEC) or co administration of albendazole with DEC in the clearance of Wuchereria bancrofti microfilaria carriers in Pondicherry, south India hospital based study. Filaria J 2002;1:2871–81
   Google Scholar
• Critchley J, Addiss D, Ejere H, et al. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 2005;9:818–25
   Web of Science ®Google Scholar
• Sutanto I, Boreham PF, Munawar M, et al. Adverse reaction to a single dose of diethylcarbamazine in patients with Brugia malayi infection in Riau Province, West Indonesia. Southeast Asian J Trop Med Public Health 1985;16:395–400
   PubMedGoogle Scholar
• Haarbrink M, Abadi GK, Buurman WA, et al. Strong association of IL-6 and lipo polysaccharide-binding protein with severity of adverse reactions after DEC treatment of microfilaremic patients. J Infect Dis 2000;182:564–9
   PubMed Web of Science ®Google Scholar
• Shieh MJ, Hsu CH, Huang LY, et al. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011;152:418–25
   PubMed Web of Science ®Google Scholar
• Li PY, Lai PS, Hung WC, et al. Poly (L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010;11:2576–82
   PubMed Web of Science ®Google Scholar
• Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011;23:6184–94
   Web of Science ®Google Scholar
• IBM Nanoparticle Breakthrough Destroys Drug-Resistant Bacteria Business 2.0 press. Available from: business2press.com [last accessed 4 April 2011]
   Google Scholar
• Slatko BE, Taylor MJ, Foster JM. The Wolbachia endosymbiont as an anti–filarial nematode target. Symbiosis 2010;51:55–65
   PubMed Web of Science ®Google Scholar
• Taylor MJ. Wolbachia endosymbiotic bacteria of filarial nematodes. A new insight into disease pathogenesis and control. Arch Med Res 2002;33:422–4
   PubMed Web of Science ®Google Scholar
• Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935–40
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Subcutaneous administration of liposomes for lymphatic targeting. Adv Drug Deliv Rev 1997;7:227–40
   Google Scholar
• Kim CK, Han JH. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 1995;12:437–46
   PubMed Web of Science ®Google Scholar
• Maincent P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 1992;9:1534–9
   PubMed Web of Science ®Google Scholar
• Reddy ST, Vlies AJ, Simeoni E. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnology 2007;25:1159–64
   PubMed Web of Science ®Google Scholar
• Ali M, Afzal M, Bhattacharya SM, et al. Nanopharmaceuticals to target antifilarials: a comprehensive review. Expert Opin Drug Deliv 2013;10:665–78
   PubMed Web of Science ®Google Scholar
• Saraf S, Ghosh A, Kaur CD, et al. Novel modified nanosystems based lymphatic targeting. J Nanosci Nanotechnol 2011;1:60–74
   Google Scholar
• Drobnik J. Hyaluronan in drug delivery. Adv Drug Deliv Rev 1999;7:295–308
   Web of Science ®Google Scholar
• Hauff, P, Reinhard M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231:667–73
   PubMed Web of Science ®Google Scholar
• Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 2008;16:798–805
   PubMed Web of Science ®Google Scholar
• Xie Y, Bagby TR, Cohen MS, et al. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 2009;6:785–92
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;23:55–64
   Web of Science ®Google Scholar
• McElroy M, Hayashi K, Susini BG. Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo. J Surg Res 2009;151:68–73
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463–78
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283–318
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297–315
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006:66
   Google Scholar
• Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 2012;19:3103–27
   PubMed Web of Science ®Google Scholar
• Kumar S, Aaron J, Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat Protocols 2008;3:314–20. Available from: http://www.nature.com/nprot/journal/v3/n2/full/nprot.2008.1.html
   PubMed Web of Science ®Google Scholar
• Xu H, Aguilar ZP, Yang L. Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials 2011;36:9758–65
   Web of Science ®Google Scholar
• Mak JW, Navaratnam V, Ramachandran CP. Experimental chemotherapy of lymphatic filariasis – a review. Ann Trop Med Parasitol 1991;85:131–7
   PubMed Web of Science ®Google Scholar
• Gupta S, Srivastava AK. Biochemical targets in filarial worms for selective antifilarial drug design. Acta Parasitol 2005;50:1–18
   Web of Science ®Google Scholar
• Lazdins J, Kron M. New molecular targets for filariasis drug discovery. Parasitol Today 1999;15:305–6
   PubMedGoogle Scholar
• Townson S, Ramirez B, Fakorede F, et al. Challenges in drug discovery for novel antifilarials. Expert Opin Drug Discov 2007;2:63–73
   PubMed Web of Science ®Google Scholar
• Singh SK, Goswami K, Sharma RD, et al. Novel microfilaricidal activity of nanosilver. Int J Nanomedicine 2012;7:1023–30
   PubMed Web of Science ®Google Scholar